Wen Chin Huang

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells
    Wen Chin Huang
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Biol Chem 285:7947-56. 2010
  2. pmc Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells
    Wen Chin Huang
    Uro Oncology Research Program, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Mol Cancer Res 10:133-42. 2012
  3. pmc Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells
    Sajni Josson
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 8:e68366. 2013
  4. pmc SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer
    Xiangyan Li
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Oncotarget 7:12869-84. 2016
  5. pmc MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells
    Xiangyan Li
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    PLoS ONE 8:e70987. 2013
  6. pmc Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations
    Xiangyan Li
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Oncotarget 6:41018-32. 2015
  7. pmc β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells
    Sajni Josson
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 71:2600-10. 2011
  8. pmc Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling
    Xiangyan Li
    Authors Affiliations Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California and Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi an, Shaanxi, China
    Mol Cancer Ther 13:855-66. 2014

Collaborators

Detail Information

Publications8

  1. pmc Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells
    Wen Chin Huang
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Biol Chem 285:7947-56. 2010
    ....
  2. pmc Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells
    Wen Chin Huang
    Uro Oncology Research Program, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Mol Cancer Res 10:133-42. 2012
    ....
  3. pmc Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells
    Sajni Josson
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 8:e68366. 2013
    ..Therefore, we hypothesized that β2-M is a rational target to treat prostate cancer bone metastasis...
  4. pmc SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer
    Xiangyan Li
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Oncotarget 7:12869-84. 2016
    ....
  5. pmc MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells
    Xiangyan Li
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    PLoS ONE 8:e70987. 2013
    ..Restoration of miR-185 and 342 led to caspase-dependent apoptotic death in prostate cancer cells. The newly identified miRNAs, miR-185 and 342, represent a novel targeting mechanism for prostate cancer therapy. ..
  6. pmc Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations
    Xiangyan Li
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Oncotarget 6:41018-32. 2015
    ..These data suggest for the first time that fatostatin alone or in combination with docetaxel could be exploited as a novel and promising therapy for metastatic PCa harboring p53 mutations. ..
  7. pmc β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells
    Sajni Josson
    Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Cancer Res 71:2600-10. 2011
    ..These results demonstrate the role of β2-M in cancer metastasis and lethality. Thus, β2-M and its downstream signaling pathways are promising prognostic markers of cancer metastases and novel therapeutic targets for cancer therapy...
  8. pmc Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling
    Xiangyan Li
    Authors Affiliations Uro Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California and Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi an, Shaanxi, China
    Mol Cancer Ther 13:855-66. 2014
    ..Our findings identify SREBP inhibition as a potential new therapeutic approach for the treatment of prostate cancer...